Search results
Arcutis shares surge on robust Zoryve franchise sales; stock PT raised by Needham By Investing.com
Investing.com· 22 hours agoThe substantial growth in Zoryve sales was attributed to continuous improvements in gross-to-net...
Summer Hair Savior: Unveiling the Power of Olive Oil for Luscious Locks
Grazia USA· 3 days agoBeat summer hair woes with olive oil! Discover its benefits and DIY hair mask tips. Plus, our top...
The Best Appetite Suppressants and Diet Pills To Control Hunger and Boost Metabolism in 2024
Men's Journal· 18 hours agoCurb cravings and sustain your energy with safe and effective appetite suppressants. When paired...
Earnings call: Almirall targets leadership in medical dermatology with Q1 growth
Investing.com· 3 days agoAlmirall, the pharmaceutical company specializing in medical dermatology, outlined a solid start to...
CDSCO approves antibody for rare skin disorder in Indian adults
Investing.com· 1 day agoCDSCO approves antibody for rare skin disorder in Indian adults
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 10 hours agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show...
Digital Journal· 6 days agoORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this
MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at Needham & Company LLC
ETF DAILY NEWS· 5 days agoNeedham & Company LLC reissued their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports ...
Japan's Takeda Pharma to restructure after annual profit slump
Reuters· 7 days ago, opens new tab announced a restructuring on Thursday after annual profit slid by more than half...
Takeda tackles $900m restructuring plan after generics hurt annual profits
Pharmaceutical Technology via Yahoo Finance· 7 days agoThese programs involve therapies to treat rare blood disorders, psoriasis and neurological...